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Plant based insect repellent and insecticide treated bed nets
to protect against malaria in areas of early evening biting
vectors: double blind randomised placebo controlled clinical
trial in the Bolivian Amazon
N Hill, principal science officer,1 A Lenglet, research fellow,1 A M Arne´z, senior clinical scientist,2
I Carneiro, lecturer1
ABSTRACT
Objective To determine the effectiveness in reducing
malaria of combining an insect repellent with insecticide
treated bed nets compared with the nets alone in an area
where vector mosquitoes feed in the early evening.
Design A double blind, placebo controlled
cluster-randomised clinical study.
Setting Rural villages and peri-urban districts in the
Bolivian Amazon.
Participants 4008 individuals in 860 households.
Interventions All individuals slept under treated nets;
one group also used a plant based insect repellent each
evening, a second group used placebo.
Main outcome measure Episodes of Plasmodium
falciparum or P vivaxmalaria confirmed by rapid
diagnostic test or blood slide, respectively.
ResultsWe analysed 15174 person months at risk and
found a highly significant 80% reduction in episodes of
P vivax in the group that used treated nets and repellent
(incidence rate ratio 0.20, 95% confidence interval 0.11
to 0.38, P<0.001). Numbers of P falciparum cases during
the study were small and, after adjustment for age, an
82% protective effect was observed, although this was
not significant (0.18, 0.02 to 1.40, P=0.10). Reported
episodes of fever with any cause were reduced by 58% in
the group that used repellent (0.42, 0.31 to 0.56,
P<0.001).
Conclusions Insect repellents can provide protection
against malaria. In areas where vectors feed in the early
evening, effectiveness of treated nets can be significantly
increased by using repellent between dusk and bedtime.
This has important implications in malaria vector control
programmes outside Africa and shows that the combined
use of treated nets and insect repellents, as advocated for
most tourists travelling to high risk areas, is fully justified.
Registration NCT 00144716.
INTRODUCTION
Bed nets impregnated with insecticide are highly
effective at reducing morbidity and mortality from
malaria.1 Most successful reports have been from
sub-Saharan Africa, where the most important vector
species, Anopheles gambiae, feeds indoors overnight.2
Malaria vectors in other parts of the world, however,
are less readily controlled by treated bed nets,
particularly those species that prefer to feed outdoors
or those that feed in the early evening.2 3 In areas of
nocturnal African vectors, researchers have expressed
concern that widespread use of treated nets may bring
forward feeding behaviour.4 As sporozoite positive
females feed earlier than other mosquitoes,5 this
might also increase the risk of transmission.
Malaria is the most serious parasitic disease in
humans, and improvements in prevention are a global
priority for those living in or travelling to endemic
areas.6 In the absence of a reliable vaccine and with
emerging drug resistance, methods of personal protec-
tion are increasingly important for travellers visiting
high risk areas. Each year around 2000 people return
to the UK with malaria, and in 2003, 16 died.7
Travellers to tropical countries commonly use insect
repellents applied to the skin to protect against biting
insects, and this, along with treated bed nets, is
recommended by most general practitioners, travel
clinics, and travellers’ health guides.8-10 Despite their
widespread acceptance and use,11 insect repellents
applied to the skin have not been shown to protect
against disease under normal conditions, although
when the insecticide permethrin was combined with a
repellent in a soap formulation and left to dry on the
skin, it offered protection from malaria.12
About 36% of the population of the Americas live in
areas with a risk ofmalaria, which includes around 293
million people in 21 endemic countries.13 Of the 1.14
million cases of malaria reported in the Americas
during 2000, 87% were recorded in the Amazonian
subregion of South America.13 The primary malaria
vector in the Amazon, A darlingi, has a peak biting
activity between 8 pm and 10 pm, and more than
80% of feeding occurs before most local people go to
bed,where they canbeprotectedby a treatedbednet.14
Given the early evening feeding activity of the local
vector, treated nets will probably need to be supple-
mented in the few hours just after dusk by some other
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control measure to obtain a high level of control. Field
evaluations of several plant-based insect repellents and
a N,N-diethyl-m-toluamide (DEET) standard in this
region found that one particular substance, Eucalyptus
maculata citriodon, provided a high degree of protection
(>98%) against A darlingi for up to four hours.3 We
selected a plant based repellent aswe consider a natural
product has the potential for local production, making
it a more readily available, cheaper, and thus a more
sustainable option for potential large scale use.
We evaluated the clinical benefit of the combined
use of insect repellent and treated bed nets in reducing
malaria in an area of evening biting vectors.
METHODS
Recruitment
The study was carried out between March and
September 2003 in all the rural communities of
Vaca Diez and Pando Provinces, Department of Beni,
in the Bolivian Amazon Region, plus the outer 10% of
theperi-urbandistricts of the twomajor towns in thearea,
Riberalta andGuayaramerin.We recruited up to 20% of
households in any one location, and each study house
was located a minimum of 25 metres from any other in
the study to avoid any effect of diversion of insects from
treatment to placebo homes. Researchers collected base-
line data (age, sex, occupation) for each participant and
obtained written informed consent from each individual
or carer of those aged under 18. Participants were
allowed to withdraw at any point in the study.
Routine data collected at the health centres reported
an annual parasite index for P falciparum of 100/1000
population. We calculated the required sample size
needed to detect a 30% reduction in the primary out-
come of P falciparum incidence, assuming a baseline
prevalence of 0.1 episodes a year with 90% power to
detect the effect at the 95% significance level. We used
the methods of Hayes and Bennett15 for cluster
randomised trials with an inter-cluster correlation
coefficient of 0.25 and estimated that we needed to
recruit and follow-up 408 households in each arm
with an average of five individuals per household for
the full six month transmission season.
Intervention
Field staff followed the strict inclusion criteria to
randomise participants at the household level
following a basic sequential alternate A/B/A/B
regimen. Field staff and study participants were blind
to the group allocation. After we recorded baseline
parameters, all participants received a freshly impreg-
nated treated bed net (25 mg/m2 deltamethrin) plus
either the insect repellent (Eucalyptus maculata citriodon)
with a p-menthane 3,8 diol (PMD) concentration of
30% (MASTA, UK) for the treatment group or 0.1%
clove oil for the placebo group. Treated nets were also
provided to participants in households not enrolled in
the study to reduce risks of short range diversion of
mosquitoes. Treatment and placebo lotions looked
and felt the same, were in identical bottles marked
A or B, and had a similar alcohol base formulation
and strong natural plant fragrance, but laboratory trials
have previously shown that clove oil is ineffective at
repelling mosquitoes (N Hill, personal communica-
tion, 2003). Individuals were shown how to apply
lotion to exposed legs, arms, and neck using a pre-
measured volume of 10 ml in the bottle cap.
Participants applied lotion at dusk each evening.
Compliance was monitored by questionnaire and
verified by local field staff recording amounts used at
monthly follow-up visits and through unannounced
evening “sniff checks.” To enable a per protocol
analysis of efficacy, we considered any individual
who reported that they had not used repellent on any
three nights (10%) each month or who had more than
30 ml (10%) lotion left as non-compliant and excluded
them from analysis for that month.
Assessments
We recorded malaria infection (with or without fever)
at baseline early in the malaria season in March and at
active monthly follow-up visits between April and July
using P falciparum specific rapid diagnostic test (Para-
check dip stick, Orchid PVT, India). As a secondary
outcome, the local health district clinic passively
detected P vivax episodes by microscopic blood slide
examination, which was subsequently validated at the
central regional health district malaria laboratory in
Randomisation (860 households, 4008 individuals)
Four month study period
Placebo 
(424 households,
1967 individuals)
Repellent 
(436 households,
2041 individuals)
Person months at risk
  (n=7868)
Withdrew from trial (n=92)
Lost to follow-up (n=198)
Non-compliance
  (n=110; 1.5%)
Person months at risk
  (n=8164)
Withdrew from trial (n=108)
Lost to follow-up (n=231)
Non-compliance
  (n=119; 1.5%)
Households analysed (n=424)
Person months analysed
  (n=7468)
Households analysed (n=436)
Person months analysed
  (n=7706)
Study flow of trial
Table 1 | Baseline characteristics of participants and incidence ofmalaria data by treatment
group. Figures are numbers (percentages) unless stated otherwise
Placebo Repellent
Households enrolled 424 436
Household television ownership 81 (19) 107 (24)
Individuals enrolled 1967 2041
Mean (SD) age (years) 29.7 (16.9) 29.9 (16.8)
Female 878 (46.3) 934 (47.2)
Positive for P falciparum 1 (0.05) 6 (0.3)
Non-compliant person months excluded from analysis 110 (1.5) 119 (1.5)
Person months at risk analysed 7468 7706
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Riberalta or Guayaramerin. All patients with positive
results were referred to the local health centre for
prompt treatment: chloroquine and primaquine for
P vivax or artesunate and mefloquine for P falciparum.
At each visit researchers asked about and recorded any
adverse events.
Statistical analysis
To assess the efficacy of the intervention the analysis
included all individuals randomised, but only for the
period of time that they were compliant with the
intervention. We used Stata 8 with a Poisson regression
model to account for the distribution of incidence rates.
As the intervention was allocated at the household level,
and individual riskwithin the samehousehold isprobably
similar because of exposure to other factors, we adjusted
for this non-independence of individuals from the same
household (intracluster correlation). As there were few
episodes of P falciparum, we accounted for the intracluster
correlation by using robust cluster methods.16 For P vivax
and general fever reports, we accounted for the intra-
cluster correlation by using random effects (generalised
estimating equation) methods. Because of the potential
for relapses, all participants with an episode of P vivax
were censored at that point and we excluded subsequent
episodesandperson timeof follow-up fromtheanalysis of
P vivax incidence. We adjusted analyses for age as an a
priori covariate because of the effect of age acquired
immunity on malaria infection.
RESULTS
The figure shows details of the numbers randomised
and the flow through the study. There were no
significant differences in most household character-
istics (number of household members, roof material,
water source, heating source, or possession of
electricity, fridge, and radio) between the two groups
(data not shown), but households allocated to the
repellent group were slightly more likely to own a
television than those allocated to the placebo group
(P=0.056) (table 1). There were also no significant
differences in age or sex between the groups but at
baseline more participants in the repellent group
were positive for P falciparum (P=0.065) (table 1).
No adverse events were reported.
As compliance was high for this type of study, with
just 1.5% person months excluded in each group, the
results of our per protocol analysis would be similar to
an intention to treat analysis. The number of
P falciparum episodes detected was low, and all
episodes in the placebo group were in children
(age 10-14), while the single episode in the repellent
group was in an adult (56 years old) (table 2).
Univariate regression analysis suggested an effect of
borderline significance, with an 84% reduction in
incidence of P falciparum in the repellent group
(P=0.091). The univariate effect of age group, however,
was highly significant with a 95% reduction in
incidence in adults (≥15 years) comparedwith children
aged 10-14 (P=0.005). After we accounted for age, the
effect of the repellent on incidence of P falciparum
remained but was even less significant (incidence rate
ratio 0.18, 95% confidence interval 0.02 to 1.40,
P=0.102).
Analysis of first episodes of P vivax showed a
reduction in those who used repellent, and again
there was a significant influence of age, with a 53%
lower incidence in adults compared with children
(P=0.002). Even after adjustment for the effect of age,
the repellent provided 80% protection (0.20, 0.11 to
0.38, P<0.001).
Similarly, for the analysis of all episodes of fever
(reported fever in the past month) there was a 59%
reduction in the group that used repellent (P<0.001),
a 42% lower incidence of fevers in adults compared
with children (P<0.001), and a borderline 56% higher
incidence of fevers (P=0.061) in those living in larger
households (six or more people) compared with those
in smaller households (fewer than six). After
adjustment for these factors, there was 58% lower
incidence of reported fevers in the repellent compared
with the placebo group (0.42, 0.31 to 0.56, P<0.001).
DISCUSSION
This randomised controlled trial shows that insect
repellent applied to the skin has a significant epidemio-
logical impact on the incidence of malaria. This
difference was detected in people who were also sleep-
ing under insecticide treated nets, highlighting the
value of additional methods of protection in areas
where malaria transmission occurs mainly in the
early evening before treated nets are used.
The large effect of the use of repellent on the
incidence of P falciparum and P vivax suggests that
most malaria transmission occurs in the early evening,
before people are protectedby sleepingunder a treated
bed net. Our results on the effect of the repellent on the
incidence of P falciparum, however, probably reflect
insufficient statistical power because of the overall
low incidence of falciparum cases during the study.
This might have been because of an unexpected
round of outdoor fogging with lambdacyhalothrin by
some health districts for a few days mid-way through
the trial, which probably temporarily reduced the
numbers of local adult mosquitoes, or simply a
fluctuation in annual incidence, which is common in
South America because of the influence of environ-
mental conditions such as El Niño.
We found clear evidence to support the use of a
combination of insect repellent and treated bed nets
as personal protection against malaria. This is
particularly important to the growing number of
Table 2 | Age specific incidence per 1000person years (episodes/personmonths at risk) of
different outcomes by treatment group
Age 10-14 years Age ≥15 years
Repellent Placebo Repellent Placebo
P falciparum 0.0 (0/1641) 40.0 (6/1801) 2.0 (1/6065) 0.0 (0/5667)
P vivax 36.8 (5/1629) 185.7 (27/1745) 17.9 (9/6044) 83.7 (39/5591)
All cause fever 197.4 (27/1641) 719.6 (108/1801) 170.2 (86/6065) 343.0 (162/5667)
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tourists and business travellers, who have no immunity
to malaria. Health professionals and specialist travel
health organisations should strongly advocate such
combined measures in high risk areas, particularly
with early evening or outdoor feeding vectors.
Having established that insect repellents canprovide
important clinical protection against malaria, we
consider their potential use against other insect-borne
diseases should be investigated. Ideal targets could
include arboviral infections, such as dengue and West
Nile fever, transmitted by daytime and outdoor biting
culicine mosquito vectors, and leishmaniasis carried
by sandflies.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Insecticide treated bed nets are a highly effective means of reducing morbidity and mortality
from malaria in Africa, where local vectors bite indoors late at night
Insect repellents can reduce mosquito bites but protection against insect-borne disease is
not clear
WHAT THIS STUDY ADDS
Treated bed nets should not be used as the only means of preventing malaria in areas where
vectors feed mainly in the evening
Use of an insect repellent can significantly reduce the risk of malaria
The combined use of a repellent and a treated bed net should be advocated to those
travelling to malaria risk areas
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